Drug Search Results
More Filters [+]

Gavorestat

Alternative Names: gavorestat, at-007, at007, at 007
Latest Update: 2024-05-30
Latest Update Note: Clinical Trial Update

Product Description

AT-007 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed for the treatment of several rare diseases.

Mechanisms of Action: AKR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Fast Track - Galactosemias
Orphan Drug - Congenital Disorders of Glycosylation
Orphan Drug - Galactosemias
Orphan Drug - SORD Deficiency
Priority Review - *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Applied Therapeutics
Company Location: NEW YORK NY 10017
Company CEO: Shoshana Shendelman
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Gavorestat

Countries in Clinic: Czech Republic, Italy, United Kingdom, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Galactosemias|SORD Deficiency

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2022-000491-18

P3

Active, not recruiting

SORD Deficiency

2026-01-14

INSPIRE

P3

Active, not recruiting

SORD Deficiency

2024-07-31

66%

AT-007-1002

P3

Active, not recruiting

Galactosemias

2023-04-01

51%

AT-007-1001

P2

Completed

Galactosemias

2021-12-14

Recent News Events